Skip to main content
As aspiring health professionals, we were very interested in the easy-to-use COVID-NoLab and COVID-SimpleLab prognostic tools. In response to the ongoing COVID-19 pandemic, we recognize the need for efficiency and accuracy in diagnosing COVID-19 infections.
In reviewing the article, we noticed that asthma was included in the COVID-SimpleLab score, but not the COVID-NoLab score. We were wondering why this is the case. Do you feel that inclusion of asthma (“yes” or “no”) could potentially strengthen accuracy of the COVID-NoLab assessment? Further, we were also curious as to the potential of strengthening the prognostic ability of the COVID-NoLab by querying patients about history of other respiratory disease diseases and/or risks such as chronic pulmonary obstructive disease or history of smoking. As we look towards the future, we are interested to know your thoughts regarding how these risk assessments can be modified to account for COVID-19 variants. What changes could be made to these assessments to better predict the outcomes of emerging COVID-19 variants over time?